Evaluation of Hemodynamic Changes and Respiratory Physical Findings in Patients with Pulmonary Embolism

Masome Rabieepour, Khalil Ansarin, Mohamad Reza Ghafari, Morteza Ghojazadeh


Introduction: Pulmonary thromboembolism (PTE) is a potentially fatal disease with nonspecific symptoms and signs. Patients with Pulmonary embolism often have dyspnea, chest pain, haemoptysis, tachycardia tachypnea and respiratory physical finding including hypoxia and decreased ETCO2. Daily patients with Pulmonary embolism are very few in hospital course and we aimed to determine clinical and paraclinical findings in hospital pulmonary embolism patients.

Methods: we assessed in hospital course of 104 patients with pulmonary embolism with symptom (dyspnea, chest pain, and hemoptysis) and signs (tachypnea, tachycardia, DVT signs, blood pressure) and respiratory physical findings (PO2, ETCO2).

Results: majority of patients had risk factor for PTE; the most common was cancer. 21.2% of patients had apparent DVT in Doppler sonography. Isolated dyspnea (38%), chest pain with and without hemoptysis (60%) and syncope (2%) were observed in patients. Mean duration of dyspnea resolution was 3.4 days. Mean duration of chest pain resolution was 1.76 days. Mean duration of hemoptysis resolution was 2 days. 64.4% of the patients were hypoxic and mean duration of hypoxic resolution was 2.63 days. Mean duration of tachycardia resolution was 2.37 days. No relation was observed between size of PTE and mortality or hypotension and PO2. Mean ETCO2 was 23±2 mmHg and 86.5% of patients had ETCO2 lower than 28. Mean duration of ETCO2 resolution was 3.6 days. Most common physical finding that resolved later than others was ETCO2. In 32.7% of patients, ETCO2 did not resolve.


Key words: Pulmonary thromboembolism; Tachycardia; Tachypnea; Hemoptysis; Hypoxic; ETCO2


Full Text:



Timothy A Morris, Peter F Fedullo (2010). Pulmonary Thromboembolism in Murray & Nades textbook of Respiratory medicine, volume2, 5th edition. Saunders, United States of America. Page 1186-1191.

Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011; 26;123(16):1788-830.

Manganelli D1, Palla A, Donnamaria V, Giuntini C. Clinical features of pulmonary embolism. Doubts and certainties. Chest. 1995;107(1 Suppl):25S-32S.

Meneveau N1, Ming LP, Séronde MF, Mersin N, Schiele F, Caulfield F, Bernard Y, Bassand JP. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J. 2003;24(15):1447-54.

Rumpf TH1, Krizmaric M, Grmec S. Capnometry in suspected pulmonary embolism with positive D-dimer in the field. Crit Care. 2009;13(6):R196. doi: 10.1186/cc8197.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2022 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine